Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments

Neuropharmacology
Faik ImeriAndrea Huwiler

Abstract

The immunomodulatory drug FTY720 is presently approved for the treatment of relapsing-remitting multiple sclerosis. It is a prodrug that requires activation by sphingosine kinase 2 (SK-2) to induce T cell homing to secondary lymphoid tissue. In this study, we have investigated the role of SK-2 in experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. We show that SK-2 deficiency reduced clinical symptoms of EAE. Furthermore, in SK-2-deficient mice, the protective effect of FTY720 on EAE was abolished, while the non-prodrug FTY720-derivative ST-968 was still fully active. Protection was paralleled by reduced numbers of T-lymphocytes in blood and a reduced blood-brain-barrier leakage. This correlated with reduced mRNA expression of ICAM-1, VCAM-1, but enhanced expression of PECAM-1. A similar regulation of permeability and of PECAM-1 was seen in primary cultures of isolated mouse brain vascular endothelial cells and in a human immortalized cell line upon SK-2 knockdown. In summary, these data demonstrated that deletion of SK-2 exerts a protective effect on the pathogenesis of EAE in C57BL/6 mice and that SK-2 is essential for the protective effect of FTY720 but not of ST-968. Thus, ST-968 is a promising novel immunomodu...Continue Reading

References

Nov 1, 1986·Neurochemical Research·S Samuels, S A Schwartz
Feb 6, 2002·The Journal of Clinical Investigation·Donnasue GraesserJoseph A Madri
Apr 23, 2002·The Journal of Biological Chemistry·Volker BrinkmannKevin R Lynch
Jun 16, 2004·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Volker BrinkmannTimothy Hla
Feb 11, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·C JaillardC Lubetzki
Aug 12, 2005·The Journal of Biological Chemistry·Yugesh KharelKevin R Lynch
Aug 25, 2005·The Journal of Biological Chemistry·Padmavathi BandhuvulaJulie D Saba
Jan 24, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Regina AlemanyDagmar Meyer Zu Heringdorf
Jun 15, 2007·Critical Reviews in Oncology/hematology·Andrea Huwiler, Uwe Zangemeister-Wittke
Mar 7, 2008·Biochemical Pharmacology·Andrea Huwiler, Josef Pfeilschifter
Jul 23, 2008·Perspectives in Vascular Surgery and Endovascular Therapy·Kimon Bekelis, Nicos Labropoulos
Jul 25, 2008·European Journal of Immunology·Chiara UboldiBritta Engelhardt
Jan 3, 2009·The Journal of Biological Chemistry·Evgeny V BerdyshevViswanathan Natarajan
Jun 6, 2009·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Ruth LyckFrancois Verrey
Jul 7, 2009·Pharmacology & Therapeutics·Andrea Huwiler, Josef Pfeilschifter
Aug 1, 2009·Circulation Research·William A Muller
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
May 4, 2010·Neuroscience Letters·Alina KułakowskaRobert Bucki
Oct 30, 2010·Nature Reviews. Drug Discovery·Volker BrinkmannPascale Burtin
Apr 27, 2011·Cellular and Molecular Neurobiology·Takashi YoshinoJun-Ichi Satoh
Oct 18, 2011·Trends in Cell Biology·Michael MaceykaSarah Spiegel
Jun 22, 2012·Journal of Neuroinflammation·Ruben van DoornHelga E de Vries
Nov 19, 2013·Biochimica Et Biophysica Acta·Marc BigaudVolker Brinkmann
Jan 25, 2014·Journal of Lipid Research·Victoria A Blaho, Timothy Hla
Mar 8, 2014·British Journal of Pharmacology·Yasuyuki KiharaJerold Chun
Mar 25, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Tomas OlssonMaria Melanson
Jul 1, 2014·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Ramona HalmerKlaus Faßbender

❮ Previous
Next ❯

Citations

Aug 8, 2019·Expert Opinion on Drug Discovery·Claudia VolpiUrsula Grohmann
Feb 9, 2017·Proceedings of the National Academy of Sciences of the United States of America·Veit RothhammerFrancisco J Quintana
Nov 12, 2017·Pharmacology & Therapeutics·Andrea Huwiler, Uwe Zangemeister-Wittke
Oct 1, 2018·Current Opinion in Immunology·Mohamed Oukka, Estelle Bettelli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier & Cytokines

Some cytokines are able to cross the blood brain barrier through transport systems and enter the cerebrospinal fluid and interstitial fluid spaces. Here is the latest research on cytokines crossing the blood brain barrier and how this can affect tissues within the CNS.

Biosynthetic Transformations

Biosyntheic transformtions are multi-step, enzyme-catalyzed processes where substrates are converted into more complex products in living organisms. Simple compounds are modified, converted into other compounds, or joined together to form macromolecules. Discover the latest research on biosynthetic transformations here.